PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTreprostinil diolamine
Treprostinil diolamine
Orenitram, Remodulin, Treprostinil, Trepulmix, Tyvaso (treprostinil diolamine) is a small molecule pharmaceutical. Treprostinil diolamine was first approved as Remodulin on 2002-05-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Orenitram
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Treprostinil diolamine
Tradename
Company
Number
Date
Products
ORENITRAMUnited TherapeuticsN-203496 RX2013-12-20
5 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
orenitramNew Drug Application2024-11-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary hypertensionEFO_0001361D006976I27.20
Agency Specific
FDA
EMA
Expiration
Code
TREPROSTINIL DIOLAMINE, ORENITRAM, UNITED THERAP
2026-10-18ODE-272
TREPROSTINIL, TYVASO, UNITED THERAP
2024-03-31I-856
Patent Expiration
Patent
Expires
Flag
FDA Information
Treprostinil, Tyvaso, United Therap
118263272042-01-04U-3749
93582402028-05-05U-1849
93395072028-03-10DP
103765252027-05-14U-1849
107167932027-05-14U-1849
Treprostinil, Tyvaso Dpi, United Therap
104217292035-04-01DP
107728832030-06-11DP
101306852025-08-23DP
Treprostinil Diolamine, Orenitram, United Therap
87478972031-08-11DPU-2724, U-2725
83498922031-01-22DP
84101692030-02-13DP
84973932028-12-15DP
74170702026-07-30DP
93932032026-04-27DPU-1877
75447132024-07-14U-1475
82528392024-05-24DP
90503112024-05-24DS, DP
92789012024-05-24U-1475
94222232024-05-24DP
Treprostinil, Remodulin, United Therap
79990072029-03-29DPU-1437
95930662028-12-15DP
96049012028-12-15DP
117238872028-12-15DP
86531372028-09-05U-1437
86586942028-09-05U-1437
97135992024-12-16U-2036
100765052024-12-16DP
106953082024-12-16U-2845
91999082024-05-24U-1771
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC21: Treprostinil
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10——1——1
Pulmonary hypertensionD006976EFO_0001361I27.20——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTreprostinil diolamine
INNtreprostinil
Description
Orenitram, Remodulin, Trepulmix, Tyvaso (treprostinil diolamine) is a small molecule pharmaceutical. Treprostinil diolamine was first approved as Remodulin on 2002-05-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O.OCCNCCO
Identifiers
PDB—
CAS-ID830354-48-8
RxCUI—
ChEMBL IDCHEMBL2107815
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDRUM6K67ESG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Remodulin – United Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Orenitram – United Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tyvaso – United Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 101 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
15,892 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use